Key Takeaways
- Nonprofits and philanthropic initiatives are stepping in to de-risk early-stage rare disease research, catalyzing investment and accelerating drug development where traditional market forces fall short.
The biopharma sector has transformed countless lives with innovative therapies, yet an estimated 85-90% of rare diseases lack any approved...



![[Test]With 75 Pipeline Candidates, TIL Therapies Gain Momentum in Solid Tumor Space](https://web.insights.norstella-labs.com/resizer/v2/G3M6E2FVDNOJPCEXELJNOIKH64.jpg?smart=true&auth=b5d5c6477bcbd6c122699f47191cbafe560695783f500a6e7b10c4d270965bdc&width=400&height=225)

